

Disclaimer

Cautionary Statement Regarding Forward-Looking Statements

Statements in this release that are not historical, are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements regarding Waldencast's outlook and guidance for Fiscal 2023; and any assumptions underlying any of the foregoing. Words such as "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "predict," "project," "should," and "will" and variations of such words and similar expressions are intended to identify such forward-looking statements.

These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside the control of Waldencast, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. Important factors, among others, that may affect actual results or outcomes include, but are not limited to: (i) the inability to recognize the anticipated benefits of the transactions with Obagi Skincare and Milk Makeup; (ii) changes in general economic conditions, including as a result of continuing inflationary pressure and the COVID-19 pandemic, (iii) the ability to continue to meet Nasdaq's listing standards; (iv) volatility of Waldencast's securities due to a variety of factors, including Waldencast's inability to implement its business plans or meet or exceed its financial projections and changes; (v) the ability to implement business plans, forecasts, and other expectations, and identify and realize additional opportunities; and (vi) the ability of Waldencast to implement its strategic initiatives and continue to innovate Obagi Skincare's and Milk Makeup's existing products and anticipate and respond to market trends and changes in consumer preferences.

These and other risks, assumptions and uncertainties are more fully described in the Risk Factors section of our Registration Statement on Form F-1 (File No. 333-267053), originally filed with the Securities and Exchange Commission (the "SEC") on August 24, 2022 and as thereafter amended, and in our other documents that we file or furnish with the SEC, which you are encouraged to read.

Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those indicated or anticipated by such forward-looking statements. Accordingly, you are cautioned not to rely on these forward-looking statements, which speak only as of the date they are made. The degree to which global economic conditions and/or COVID-19 may adversely affect Waldencast's results and operations, including its ability to achieve its outlook and guidance for Fiscal 2023, will depend on numerous evolving factors and future developments, which are highly uncertain, including, but not limited to, federal, state and local governmental policies and interest rate adjustments by the Federal Reserve, the ongoing conflict in Ukraine, and initiatives designed to reduce the transmission of COVID-19 and emerging new variants and how quickly and to what extent normal economic and operating conditions can resume. As a result, the impact on Waldencast's financial and operating results cannot be reasonably estimated with specificity at this time, but the impact could be material Waldencast expressly disclaims any current intention, and assumes no duty, to update publicly any forward-looking statement after the distribution of this release, whether as a result of new information, future events, changes in assumptions or otherwise. Waldencast gives no assurance that the combined company will achieve its expectations.

Reconciliation of Non-GAAP Financial Measures

The financial information and data contained in this release have not been audited in accordance with the standards of the Public Company Accounting Oversight Board and does not conform to Regulation S-X.

Waldencast separately reports financial results on the basis of adjusted gross margin, adjusted EBITDA and adjusted EBITDA margin, which are non-GAAP financial measures. See the attached tables for a reconciliation of adjusted gross margin, adjusted EBITDA and adjusted EBITDA margin to net sales and net income (loss), which are the most directly comparable GAAP financial measures.

For Obagi Skincare, adjusted gross margin excludes the sales related to the China distributor under a transition services agreement, the impact of Obagi Skincare's related party sales to the China distributor, and the impact of the inventory fair value step-up as a result of the business combination accounting. For Milk Makeup, adjusted gross margin excludes the impact of the inventory fair value step-up as a result of the business combination accounting.

Adjusted EBITDA is defined as net income (loss) excluding the impact of income tax benefit, interest expense, net, depreciation and amortization and the transaction costs, non-cash items, and certain non-recurring income and expense that do not occur regularly as part of the normal activities of Obagi Skincare and Milk Makeup.

Adjusted EBITDA margin is defined as adjusted EBITDA divided by net sales.

Waldencast believes the non-GAAP measures of adjusted gross margin, adjusted EBITDA and adjusted EBITDA margin provide useful information to management and investors regarding certain financial and business trends relating to its financial condition and results of operations. Waldencast believes that the use of these non-GAAP financial measures provides an additional tool for investors to use in evaluating ongoing operating results and trends in comparing its financial measures with other similar companies, many of which present similar non-GAAP financial measures to investors. These non-GAAP measures also provide perspective on how Waldencast's management evaluates and monitors the performance of the business and provides a view on how the on-going operating company performs. These non-GAAP financial measures are subject to inherent limitations as they reflect the exercise of judgments by management about which expense and income are excluded or included in determining these non-GAAP financial measures.


Comparable net sales for Obagi Skincare in predecessor periods excludes sales related to its former Obagi China business.

In addition, the Company has presented the comparative quarterly results that combine the predecessor and post-acquisition periods for Obagi Skincare and the pre and post-acquisition periods for Milk Makeup. Under U.S. Generally Accepted Accounting Principles ("GAAP"), the periods prior to and subsequent to the acquisition date should not be combined, and Milk Makeup's pre-acquisition period should not be included. Management believes these non-GAAP comparative quarterly results provide a perspective on the on-going performance of the combined companies' operations.

2



Strictly confidential. Property of Waldencast.







A platform poised for long-term profitable growth



House of brands built for scale and speed



Pure-play in beauty



Diversified portfolio (category, channel, geography, price point)



Significant opportunity for accelerated long-term growth



Proven model with sustained profitability



World-class management teams with deep operating experience and expertise

US Beauty continues its strong momentum growing double-digit despite economic uncertainties





Prestige Beauty grew double digit in 2022 and has continued into early 2023, as sales continue to go up as confidence went down, another illustration of the "lipstick effect" and "treat" mindset.

Makeup back to pre-pandemic levels in units, slightly behind on value due to mix with the lower price points while the Lip category is growing fast, recovering from the pandemic mask dip.

Skin Care momentum continues, driven by the medicalisation of beauty and the desire for more effective, science backed skin care with 39% of US Skincare consumers (Gen X or Older) feel it's important for skin care products to be recommended by a doctor.

Source: NPD US March 2023. US Dollar & Units Sales Growth. Mintel 2023 Global Beauty & Personal Care Trends.

Strictly confidential. Property of Waldencast.

Waldencast has the leading brands in two of the most resilient highgrowth beauty markets



Leading physician-dispensed brand

Attractive growth potential and strong anchor capabilities in skin health, complemented by a robust financial and operational backbone

#1 Perceived best performing brand among US providers¹ Patents worldwide²



Leading clean makeup brand

Cult following among Gen-Z consumers known for its cultural relevance and iconic products. Anchored by strong community in a rapidly growing makeup segment





^{1 &}quot;2020 Kline Physician-Dispensed Skincare: US Perception & Satisfaction Survey," Kline & Company

² Obagi Information


³ Sephora management

⁴ As of March 7th, 2023 9:00am ET



Differentiated competitive advantage through a highly credentialed and sticky business model


Credentialed recommendation



Science-led rigorous testing driving transformative results



Full range of skin solutions



Highly specialized organization



We formulate leading products through three vectors of innovation

Characterization innovation

Disease state Skin conditions

Population Urbanites, country of origin

Claims

Magnitude, incidence, speed, QoL

Instrument

Cutometry, optical coherence tomography, hydration mapping, ballistometry

Benefit innovation

Performance strength

Performance speed

Indication Sagging, radiance

Ingredient innovation

Mechanism of action

Elastin maturation. collagen coiling

Technical concept Inflammaging, urbanization


Ingredient

Product form Powder-to-liquid,

anhydrous chassis



Our products outperform competitors across key attributes



Pro-C 20% serum

Leading competitor

Perioral fine

wrinkles

Mottled

hyper-

pigmentation

Periocular

wrinkles

Laxity

Sallowness


We test and demonstrate our transformative research-backed results in studies and visuals Case study: Nu-Derm®


Rendon, MD, FAAD & Chere Lucas-Anthony, MD, FAAD; Number of subjects who completed the study: 61; 1A condition in which brown patches appear on the face. **P≤.01, ***P≤.001 versus baseline; 2 Data as of week 24.





Skin condition treated: Melasma⁽¹⁾





- 4% hydroquinone skin care system + 0.025% tretinoin cream
- 4% hydroquinone skin care system + 0.05% tretinoin cream
- ▲ 4% hydroquinone skin care system + 0.1% tretinoin cream

11



OBAGI GROWTH STRATEGY COTC Mcdical

Strategic Growth Levers:

- 1. Expand US physician penetration
- 2. Expand portfolio breadth and depth
- 3. Expand US and international footprint




BUILD THE TOP GLOBAL BEAUTY BRAND FOR THE NEXT GENERATION



OUR COMMUNITY IS OUR SUPERPOWER

OUR DNA IS BUILT AROUND THEIR VALUES: SELF-EXPRESSION + INCLUSION + COMMUNITY



OUR VALUES ARE ALIGNED WITH THE NEXT GENERATION

WE BELIEVE IN DOING THE RIGHT THING FOR OUR COMMUNITY AND FOR THE PLANET

CLEAN FORMULAS













IMPROVING OUR FOOTPRINT









RE-INVESTING IN OUR COMMUNITY







Represent (Continued) Below is the breakdown of our entire team in June 2021 compared to June 2020: June 2020 June 2021 Clased on 50 employees who (Dased on 49 employees) BIPOC: 38% BLACK OR AFRICAN AMERICAN OR AFRICAN CAR BBEAN, 15% AFRICAN AMERICAN OR AFRICAN CAR BBEAN 9% ASIAN OR ASIAN AMERICAN: 8% ASIAN OR ASIAN AMERICAN: 9% HISPANIC OR LATINX: 15% HISPANIC OR LATING:14% WHITE: 56% WHITE 68% TWO OR MOSE RACES: 4% DID NOT DISCLOSE: 2% 82% WOMEN-IDENTIFYING 78% WOMEN-IDENTIFYING 16% MEN-IDENTIFYING 22% MEN-IDENTIFYING 2% GENDER FLUID

HERO PRODUCTS IN DIVERSE CATEGORIES WITH CONSISTENT GROWTH

A SOLID BASE FOR FUTURE GROWTH. THE CALLING CARDS OF THE BRAND IN NEW MARKETS.



Hydro Grip Primer \$36 3,657 ★★★★ Reviews



Sunshine Family¹ \$28 – \$42 1,217 ★★★★ Reviews²



KUSH Mascara \$26 9,200 ★★★★ Reviews







Matte Bronzer \$24 884 ★★★★ Reviews

Launch date: 2019 2021 2018 2016 2016

OUR GROWTH ROADMAP

3 KEY LEVERS

GROW AWARENESS + COMMUNITY




EXPAND + INTERNATIONALIZE DISTRIBUTION










DELIVERING BREAKTHROUGH INNOVATION

BALANCED GROWTH WITH NEW LAUNCHES
STRATEGY TO REINFORCE CORE CATEGORIES MASCARA + PRIMER WHILE EXPANDING INTO COMPLEXION






¹Sephora management

LOOKING AHEAD: SIGNIFICANT CATEGORY EXPANSION OPPORTUNITIES

KEY FOCUS: REINFORCING CORE CATEGORIES WHILE WINNING IN NEW COMPLEXION BATTLEGROUND




¹ Market sizes reflect 2021E data for the USA market; Euromonitor International; Beauty & Personal Care and Color Cosmetics in the US, 2021ed, retail value sales, current prices, 2020 fixed ex rates

² Primer refers to EMI's category BB/CC creams and skin tints refers to EMI's premium foundation / concealer

³ Areas where management believes product offering expansions or introduction of new categories are possible

⁴ Milk internal sku count

EXPAND + INTERNATIONALIZE DISTRIBUTION



Note: Door counts represent expansion opportunities in brick and mortar stores Source: Retailer company websites



This is only the beginning...

TODAY

OBAGI
















FUTUREOptimized multi-brand portfolio spanning:



A platform poised for long-term profitable growth characterized by:

- Operational scale of a multibrand platform
- Balanced portfolio in structurally attractive segments of the category
- Expertise in managing global beauty brands at scale
- Asset-light efficiency vs. slow, inflexible and costly traditional structures
- Strong alignment of management incentives to long-term value creation thru operational and capital allocation excellence

2 leading brands with
unique positioning
anchored in high customer
affinity and strong brand
equity

OBAGI



Resilient and high-growth
markets that have
weathered the macro
turmoil faced by
consumer markets

+16%

BeautyQ1 2023
Value Growth

+24%

Make Up Q1 2023 Value Growth

+11%

Skin Care Q1 2023 Value Growth







Waldencast commitment to exemplary ESG



MMU Sustainability Commitments:

More Sustainable shipping + Outer Packaging

More Environmentally friendly packs + Refills


How To Recycle Partnerships with How2Reycle and

g2 revolution



MMU social philanthropy focuses on self-expression and equality for underrepresented LGBTAIQ+ and BIPOC groups.

SKINCLUSION is Obagi's commitment to provide effective, science-based skin care for all skin tones. They were the 1st to design clinical research on all six Fitzpatrick skin types.



Public Company Best in Class governance with Best In Class board of Directors and Protocols.

24



Strictly confidential. Property of Waldencast.